Atreca, Inc. - (BCEL) News
Filter BCEL News Items
BCEL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest BCEL News From Around the Web
Below are the latest news stories about ATRECA INC that investors may wish to consider to help them evaluate BCEL as an investment opportunity.
Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic AlternativesSAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today reported financial results for the third quarter ended September 30, 2023, and announced that the Company is implementing a further reduction in its workforce of approximately 40% while maintaining the necessary supp |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the trading week right with a breakdown of the biggest pre-market stock movers worth noting on Monday morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to dive into the biggest pre-market stock movers for Friday with all the shares investors will want to keep an eye on today! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about this morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic worth checking out on Wednesday and we have all the latest news happening this morning! |
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb CrossSAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that, as part of its ongoing efforts to lower operating expenses, the Company has entered into an agreement to terminate its lease agreement pertaining to the Company's headquarters in San Carlos, CA, whic |
While dollars continue to flow into biotech, companies cut more jobsBiotech continues to have a big impact on the local and state economy, a new report says. But mature clinical-stage companies also are struggling. |
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%. |
Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate RestructuringSuspending development of ATRC-101 Cost-saving measures include 40% workforce reduction Focusing on advancing earlier stage ADC candidates and preserving discovery capabilities SAN CARLOS, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the sec |
3 Penny Stocks to Catapult You Into the Millionaires’ ClubThese penny stocks can deliver tremendous upside from their depressed range. |